Adult Vaccine Market Size And Forecast Report 2024-2032
Global Adult Vaccine Market Analysis
The global adult vaccine market is poised for significant growth, with an estimated market size of US$ 20.59 billion in 2023 and projected to reach US$ 35.87 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.36% from 2024 to 2032. This growth is primarily driven by the rising incidence of infectious diseases, a growing aging population, and increasing awareness about the importance of immunizations in adults.
Request a free sample copy of the report: https://www.renub.com/adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php
Market Overview: What Are Adult Vaccines?
Adult vaccines are designed for individuals aged 18 and above to prevent infectious diseases, mitigate complications, and reduce the transmission of pathogens. As immunity from childhood vaccinations may wane over time, adults require booster shots or new immunizations to remain protected. These vaccines help prevent illnesses like influenza, pneumonia, shingles, human papillomavirus (HPV), hepatitis, and other infectious diseases.
For instance:
- Flu Vaccines: Annually recommended, especially for high-risk groups such as the elderly and pregnant women.
- Tetanus, Diphtheria, Pertussis (Tdap): A booster vaccine required every 10 years to protect against diseases like whooping cough.
- Pneumococcal Vaccines: Recommended for adults aged 65 and older to protect against pneumonia, meningitis, and bloodstream infections caused by Streptococcus pneumoniae.
- Herpes Zoster Vaccine: Aimed at preventing shingles in adults over 50, which can be a painful and debilitating condition.
Key Drivers of Growth
1. Rising Prevalence of Adult Diseases
As populations globally age, the prevalence of chronic and infectious diseases in adults is increasing. This trend is particularly notable in regions like North America and Europe, where chronic illnesses such as obesity, diabetes, and cardiovascular disease are common. According to the CDC, flu-related hospitalizations in the US can be reduced by nearly 90,000 annually through vaccination, which highlights the critical role adult vaccines play in public health.
Moreover, pneumococcal disease remains one of the leading causes of death in elderly adults, with approximately 500,000 deaths annually worldwide, according to the World Health Organization (WHO). As the global population continues to age—by 2030, it’s expected that one in six people will be over the age of 65—the need for adult vaccines will continue to rise.
2. Increased Infectious Disease Transmission
Recent years have underscored the importance of adult immunization in controlling infectious disease outbreaks. The ongoing COVID-19 pandemic has heightened awareness of the significance of vaccines in mitigating public health risks. The emergence of new diseases, such as respiratory syncytial virus (RSV), which has led to increased cases among the elderly, further fuels the demand for adult vaccines.
3. Government and Healthcare Initiatives
Governments around the world, particularly in North America and Europe, have been actively promoting vaccination programs. In the US, for instance, the CDC and NIH recommend vaccinations for a wide range of diseases, including seasonal flu and pneumococcal disease. These initiatives are supported by increasing investments in public health infrastructure and collaborations between pharmaceutical companies and government agencies to enhance vaccine access.
Market Trends and Innovations
The biopharmaceutical industry is playing a key role in the development of new vaccine candidates. A notable example is GSK’s Arexvy, the first RSV vaccine, which was approved by the U.S. FDA in May 2023 for adults aged 60 and older. This marks a significant breakthrough in combating respiratory illnesses in older adults. Additionally, pharmaceutical giants like Merck and Pfizer are investing in next-generation vaccines that target a variety of infectious diseases, including COVID-19, influenza, and pneumococcal infections.
In April 2024, Merck released promising results from its Phase 3 trial of V116, a 21-valent pneumococcal conjugate vaccine. The trial demonstrated the vaccine’s potential to offer better protection against pneumonia for older adults. This innovation is expected to play a crucial role in reducing the impact of pneumonia-related illnesses among high-risk populations.
Regional Market Insights
North America
North America, particularly the United States, is expected to continue dominating the adult vaccine market due to high vaccination rates and government-led initiatives. The CDC’s recommendation for annual flu vaccinations, as well as pneumococcal and herpes zoster vaccines for older adults, further boosts demand. In the US, the influenza vaccine alone is responsible for preventing nearly 90,000 hospitalizations annually.
The rise in viral infections, such as influenza and RSV, alongside the growth in chronic conditions like obesity, is expected to propel the adult vaccine market in this region. In 2023, 22 states in the US had obesity rates above 35%, highlighting the need for vaccination programs targeting chronic and infectious diseases among adults.
Europe and Asia-Pacific
Europe and the Asia-Pacific region are also witnessing strong growth in the adult vaccine market. In particular, China, with its large aging population, presents significant opportunities for vaccine manufacturers. The push for public health reforms in India and other emerging markets will likely contribute to increased vaccine accessibility in these regions.
Challenges in the Adult Vaccine Market
Despite strong growth prospects, there are challenges that could affect the market’s expansion:
- Vaccine Hesitancy: Public skepticism towards vaccines, especially following the COVID-19 pandemic, could hinder widespread adoption in certain populations.
- Access and Affordability: In developing regions, economic barriers and insufficient healthcare infrastructure may limit access to adult immunizations.
Competitive Landscape: Key Players
Several major companies are leading the adult vaccine market, including:
- GlaxoSmithKline plc.
- AstraZeneca plc.
- Sanofi Pasteur
- Pfizer, Inc.
- CSL Limited
These companies are actively involved in the development and distribution of vaccines targeting adult populations. They are leveraging partnerships with governmental health organizations and the private sector to enhance vaccine accessibility and drive innovation in the vaccine market.
Related Report :
United States Pain Management Therapeutics Market
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: mailto:rajat@renub.com